VIRVir Biotechnology, Inc.
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical dev…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript HDV combination therapy achieved 88% viral clearance, advancing toward Phase 3 readouts. | ||
 Vir Biotechnology, Inc. Q2 2026 Earnings Call Summary Moby summary of Vir Biotechnology, Inc.'s Q2 2026 earnings call | ||
 Vir Biotechnology Q2 Earnings Call Highlights Vir Biotechnology (NASDAQ:VIR) reported second-quarter 2026 results alongside updates on its chronic hepatitis delta and oncology programs, highlighting completed enrollment in a key hepatitis delta study, plans for multiple data readouts, and expanded development activity for its prostate cancer ca | ||
Vir Biotechnology Inc (VIR) (Q2 2026) Earnings Call Highlights: 88% HDV Cure Rate and a $1B ... Vir Biotechnology Inc (VIR) reports best-in-class HDV data, completes ECLIPSE enrollment, and extends cash runway into 2028. | ||
 Vir Biotechnology, Inc. (VIR) Q2 Earnings and Revenues Miss Estimates Vir Biotechnology (VIR) delivered earnings and revenue surprises of -43.37% and -7.51%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Vir Biotechnology (VIR) Could Be 60% Undervalued On CFO Transition Vir Biotechnology (VIR) stock is in focus after Chief Financial Officer Jason O’Byrne decided to step down effective August 3, 2026, with senior finance executive Brent Sabatini appointed as the interim principal financial officer. See our latest analysis for Vir Biotechnology. Recent trading reflects this leadership change coming at a time when Vir Biotechnology’s 30 day share price return is down 9.41% and its 90 day share price return is down 13.40%. This is despite a year to date share... | ||
IInsider Monkey | ||